| Identification | Back Directory | [Name]
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[4-(aminocarbonyl)phenyl]-N-(5-cyano-2-pyridinyl)-N-methyl- | [CAS]
1610610-48-4 | [Synonyms]
KDU731
KDU731,KDU-731
3-(4-Carbamoylphenyl)-N-(5-cyanopyridin-2-yl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[4-(aminocarbonyl)phenyl]-N-(5-cyano-2-pyridinyl)-N-methyl- | [Molecular Formula]
C22H16N6O2 | [MOL File]
1610610-48-4.mol | [Molecular Weight]
396.4 |
| Chemical Properties | Back Directory | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 83.33 mg/mL (210.22 mM) | [form ]
Solid | [pka]
15.78±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo[1][2]. KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety[2]. | [in vivo]
KDU731 (orally administration; 7 or 10mg/kg; 16 days) has potent activity against Cryptosporidium in immunocompromised IFN-γ KO mice and dramatically reduces oocyst shedding[2].
KDU731 (orally administration; 5 mg/kg; every 12 hours for 7 days) is tolerated in all calves, and treated calves shed significantly fewer oocysts than vehicle treated calves in their stool[2]. | Animal Model: | 6-8 week old C57BL/6 IFN-γ-knockout mice with 10,000 oocysts[1] | | Dosage: | 7 or 10 mg/kg | | Administration: | Orally administration; 7 or 10 mg/kg; 16 days | | Result: | Resulted in significant reduction of oocyst shedding. |
| Animal Model: | Neonatal calves with 5 x 107 oocysts[1] | | Dosage: | 5 mg/kg | | Administration: | Orally administration; 5 mg/kg; every 12 hours for 7 days | | Result: | Resulted in significant reduction of oocyst shedding in treated calves in their stool. |
| [IC 50]
PI4K | [References]
[1] Ward HD, et al. New Tools for Cryptosporidium Lead to New Hope for Cryptosporidiosis. Trends Parasitol. 2017 Sep;33(9):662-664. DOI:10.1016/j.pt.2017.07.004
[2] Manjunatha UH, et al. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature. 2017 Jun 15;546(7658):376-380. DOI:10.1038/nature22337 |
|
|